Inhibition of CD38/Cyclic ADP-ribose Pathway Protects Rats against Ropivacaine-induced Convulsion

作     者：Yu Zou Xin He Qian-Yi Peng Qu-Lian Guo Zou Yu;He Xin;Peng Qian-Yi;Guo Qu-Lian

作者机构：Department of Anesthesiology Xiangya Hospital Central South University Changsha Hunan 410008 China Department of Critical Care Medicine Xiangya Hospital Central South University Changsha Hunan 410008 China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2017年第130卷第19期

页      面：2354-2360页

核心收录：

学科分类：0710[理学-生物学] 081704[工学-应用化学] 07[理学] 08[工学] 0817[工学-化学工程与技术] 071009[理学-细胞生物学] 09[农学] 070303[理学-有机化学] 0901[农学-作物学] 0703[理学-化学] 090102[农学-作物遗传育种] 

基　　金：国家自然科学基金 

主　　题：CD38 Convulsion Cyclic ADP-ribose Nicotinamide Adenine Dinucleotide Ropivacaine 

摘      要：Background： The CD38/cyclic ADP-ribose （cADPR） pathway plays a role in various central nervous system diseases and in morphine tolerance, but its role in local anesthetic intoxication is unknown. The aim of this study was to determine the role of the CD38/cADPR pathway in ropivacaine-induced convulsion. Methods： Forty male Sprague-Dawley rats were randomly divided into five groups （n = 8 per group）： sham group, ropivacaine group, ropivacaine＋8-Br-cADPR （5 nmol） group, ropivacaine＋8-Br-cADPR （10 nmol） group, and ropivacaine＋8-Br-cADPR （20 nmol） group （no rats died）. Rats were intracerebroventricularly injected with normal saline or 8-Br-cADPR 30 min before receiving an intraperitoneal injection of ropivacaine. Electroencephalography and convulsion behavior scores were recorded. The hippocampus was harvested from each group and subjected to nicotinamide adenine dinucleotide and cADPR assays, Western blotting analysis, and malondialdehyde （MDA） and superoxide dismutase （SOD） assays. Results： Intraperitoneal injection of ropivacaine （33.8 mg/kg） induced convulsions in rats. CD38 and cADPR levels increased significantly following ropivacaine-induced convulsion （P = 0.031 and 0.020, respectively, compared with the sham group）. Intraventricular injection of 8-Br-cADPR （5, 10, and 20 nmol） significantly prolonged convulsion latency （P = 0.037, 0.034, and 0.000, respectively）, reduced convulsion duration （P = 0.005, 0.005, and 0.005, respectively）, and reduced convulsion behavior scores （P = 0.015, 0.015, and 0.000, respectively）. Intraventricular injection of 8-Br-cADPR （10 nmol） also increased the B-cell lymphoma-2 （Bcl-2）/Bcl-2-associated X protein ratio （P = 0.044） and reduced cleaved Caspase 3/Caspase 3 ratio, inducible nitric oxide synthase, MDAand SOD levels （P = 0.014, 0.044, 0.001, and 0.010, respectively） compared with the ropivacaine group. Conclusions： The CD38/cADPR pathway is activated in ropivacaine-induced convulsion. Inhibiting this pathway alleviates ropiva